<?xml version="1.0" encoding="UTF-8"?>
<Progress_Report_Checklist
><Grant_Information
><RFA_Number
>06-01</RFA_Number
><Grant_Number
>RS1-00420-1</Grant_Number
><Reporting_Period_Start
>10/1/2008</Reporting_Period_Start
><Reporting_Period_End
>9/30/2009</Reporting_Period_End
><Institution_Name
>University of California, Los Angeles</Institution_Name
><Primary_Investigator
><Prefix
/><First_Name
>Hanna</First_Name
><Middle_Name
/><Last_Name
>Mikkola</Last_Name
><Suffix
/><Degree
/><Institution
/><Title
/><Department
/><Email
/><Telephone_Number
/><Extension
/><Fax_Number
/></Primary_Investigator
></Grant_Information
><Reviewer_Information
><Grants_Manager
><Prefix
/><First_Name
/><Middle_Name
/><Last_Name
/><Suffix
/><Degree
/><Institution
/><Title
/><Department
/><Email
>ewhite-negrete</Email
><Telephone_Number
/><Extension
/><Fax_Number
/></Grants_Manager
><Science_Officer
><Prefix
/><First_Name
/><Middle_Name
/><Last_Name
/><Suffix
/><Degree
/><Institution
/><Title
/><Department
/><Email
>stalib</Email
><Telephone_Number
/><Extension
/><Fax_Number
/></Science_Officer
></Reviewer_Information
><Reviews
><Budget_Review
><IsRequired
/><Grant_Manager_Notes
>NCE financial report received and approved. Grantee overspent by $92.</Grant_Manager_Notes
><Science_Officer_Notes
/><Grant_Manager_Approval
>1</Grant_Manager_Approval
><Science_Officer_Approval
>1</Science_Officer_Approval
><IsComplete
/></Budget_Review
><California_Supplier_Review
><IsRequired
/><Grant_Manager_Notes
>57% CA supplier reported</Grant_Manager_Notes
><Science_Officer_Notes
/><Grant_Manager_Approval
>1</Grant_Manager_Approval
><Science_Officer_Approval
/><IsComplete
/></California_Supplier_Review
><Key_Personnel_Review
><IsRequired
/><Grant_Manager_Notes
/><Science_Officer_Notes
/><Grant_Manager_Approval
/><Science_Officer_Approval
>1</Science_Officer_Approval
><IsComplete
/></Key_Personnel_Review
><IACUC_Assurances_Review
><IsRequired
>1</IsRequired
><Grant_Manager_Notes
>Assurance submitted: approval period from 1/14/2010-1/1/2011. Assurance does not specifically mention CIRM SEED award; SO to approve.</Grant_Manager_Notes
><Science_Officer_Notes
/><Grant_Manager_Approval
>1</Grant_Manager_Approval
><Science_Officer_Approval
>1</Science_Officer_Approval
><IsComplete
/></IACUC_Assurances_Review
><IRB_Assurances_Review
><IsRequired
>0</IsRequired
><Grant_Manager_Notes
/><Science_Officer_Notes
/><Grant_Manager_Approval
>0</Grant_Manager_Approval
><Science_Officer_Approval
>0</Science_Officer_Approval
><IsComplete
/></IRB_Assurances_Review
><SCRO_Assurances_Review
><IsRequired
>1</IsRequired
><Grant_Manager_Notes
>Assurance submitted: approval period from 10/13/2009-10/12/2010. Assurance lists CIRM SEED award.</Grant_Manager_Notes
><Science_Officer_Notes
/><Grant_Manager_Approval
>1</Grant_Manager_Approval
><Science_Officer_Approval
>1</Science_Officer_Approval
><IsComplete
/></SCRO_Assurances_Review
><Publication_Reporting_Review
><IsRequired
>0</IsRequired
><Grant_Manager_Notes
/><Science_Officer_Notes
/><Grant_Manager_Approval
>0</Grant_Manager_Approval
><Science_Officer_Approval
>0</Science_Officer_Approval
><IsComplete
/></Publication_Reporting_Review
><Invention_Licensing_Review
><IsRequired
>0</IsRequired
><Grant_Manager_Notes
/><Science_Officer_Notes
/><Grant_Manager_Approval
>0</Grant_Manager_Approval
><Science_Officer_Approval
>0</Science_Officer_Approval
><IsComplete
/></Invention_Licensing_Review
><PI_Effort_Review
><IsRequired
>1</IsRequired
><Grant_Manager_Notes
/><Science_Officer_Notes
/><Grant_Manager_Approval
/><Science_Officer_Approval
>1</Science_Officer_Approval
><IsComplete
/><Total_Current_Effort
>85</Total_Current_Effort
><CIRM_Award_Effort
>10</CIRM_Award_Effort
></PI_Effort_Review
></Reviews
><Award_Conditions
><Conditions_Exist
>0</Conditions_Exist
><Conditions_Met
><Conditions_Met
/><Grants_Manager_Notes
/><Grants_Manager_Approval
>0</Grants_Manager_Approval
><Science_Officer_Notes
/><Science_Officer_Approval
>0</Science_Officer_Approval
></Conditions_Met
><New_Conditions
><New_Conditions
>0</New_Conditions
><Grants_Manager_Notes
/><Grants_Manager_Approval
>0</Grants_Manager_Approval
><Science_Officer_Notes
/><Science_Officer_Approval
>0</Science_Officer_Approval
></New_Conditions
></Award_Conditions
><Prior_Approval
><IsRequired
>0</IsRequired
><Grant_Manager_Notes
/><Science_Officer_Notes
/><Grant_Manager_Approval
>0</Grant_Manager_Approval
><Science_Officer_Approval
>0</Science_Officer_Approval
><IsComplete
/></Prior_Approval
><OtherIssues
/><Evaluation
><Overall_Rating
>Satisfactory</Overall_Rating
><Translational_Status
>No substantial change, incremental, or N/A</Translational_Status
><Executive_Summary
>RS1-00420&#xD;&#xD;Hanna Mikkola Year 2 No Cost Extension  Final Report – Comments&#xD;&#xD;• In this grant Dr. Mikkola has investigated the role of hematopoitic stem cell niche in differentiation of hESC-derived HSC/PC .&#xD;• In last two years a two step differentiation process was developed that combines EB differentiation and subsequent stroma co-culture to produce HSC/PC  (CD34+ CD38-CD90+CD45+).&#xD;• Molecular profiling suggests hESC-derived HSC have restricted development compare to fetal liver or cord blood derived HSC and unable to generate B cells.&#xD;• In the NCE extension period PI shows results indicating similarities with early embryonic HSC isolated from human placenta&#xD;• Further, Retinoic acid induction produced CD34+ CD38+ cells&#xD;• PI also provide some evidence that hESC-derived HSC can be differentiated into T cells&#xD;&#xD;• One of the experiments that was indicated in the request for NCE was to seess the in vivo engraftment of the hESC-derived HSC in the NSG mouse. In the final progress report there is no indication that in vivo experiments were carried out. (Question sent to PI if in vivo experiments were performed or were not attempted due to insufficient yield of the differentiated product?)&#xD;&#xD;• Also ask the PI about CD150 expression on hESC-derived HSC.  CD150 has been described in the literature as a marker that predict multipotent reconstitution.&#xD;&#xD;• Overall this SEED grant has made significant contribution to the understanding of the hESC-derived HSC/PC . PI has made progress in optimizing the culture conditions for generating T-lymphoid cells in vitro from hESC. Molecular profiling data generated in this grant will be helpful in future studies to identify novel surface molecules that can be used to distinguish functional HSC from embryonic lineage restricted hematopoietic progenitors&#xD;</Executive_Summary
></Evaluation
><Strategic_Outcome
><Five_Year_Goal_1
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_1
><Five_Year_Goal_2
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_2
><Five_Year_Goal_3
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_3
><Five_Year_Goal_4
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_4
><Five_Year_Goal_5
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_5
><Five_Year_Goal_6
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_6
><Five_Year_Goal_8
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_8
><Ten_Year_Goal_1
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_1
><Ten_Year_Goal_2
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_2
><Ten_Year_Goal_5
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_5
><Ten_Year_Goal_7
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_7
><Ten_Year_Goal_8
><IsApplicable
>1</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
>Overall this SEED grant has made significant contribution to the understanding of the hESC-derived HSC/PC . PI has made progress in optimizing the culture conditions for generating T-lymphoid cells in vitro from hESC. Molecular profiling data generated in this grant will be helpful in future studies to identify novel surface molecules that can be used to distinguish functional HSC from embryonic lineage restricted hematopoietic progenitors</Outcomes
><Impact_Factor
>2</Impact_Factor
></Ten_Year_Goal_8
><Ten_Year_Goal_9a
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_9a
><Ten_Year_Goal_9b
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_9b
><Ten_Year_Goal_10
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_10
><OtherOutcomes
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></OtherOutcomes
></Strategic_Outcome
><IsComplete
/></Progress_Report_Checklist
>